Lexeo Therapeutics Inc. Common Stock (LXEO)

FairStock Score: 54/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-style investor, I start with what is proven. Lexeo has no revenue in the filed periods and has lost money in each of the last four years. In fiscal 2025, net income was -$100.0 million; in fiscal 2024, -$98.3 million; in fiscal 2023, -$66.4 million. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$25.9 million, and in fiscal Q1 2026 it was -$20.2 million. Trailing free cash flow is -$88.7 million, a -39.5% FCF yield against the $224.8 million market cap. That is not owner earnings; it is investor-funded pipeline spending. The balance sheet has low leverage, with D/E 0.03 and an Altman Z-Score of 5.41 per FairStock, but the Piotroski F-Score is 1/9 and ROE/ROCE are -46.76%/-27.59%, also FairStock calculations. At the 2026-10-13 close of $2.74, P/B is 0.92 and P/E is -3.11. A sub-book price can suggest asset protection, but here book value is being consumed and future value depends on clinical trials for LX2006, LX2020, and LX2021. Gene therapy may have a large opportunity, but no durable moat exists until approval, manufacturing, and reimbursement are proven. FairStock score 54/100 and Lynch category none — loss in each of the last 4 years — fit a speculative, binary situation. I would need trial success, slower cash burn, and a credible path to revenue before calling the low price a margin of safety.

In plain English: Lexeo Therapeutics is a small clinical-stage biotech trying to develop gene therapies for serious heart and other diseases. It does not yet sell a product, has no reported revenue, and has lost money in each of the last four years, so the business itself looks weak today. The stock trades near its 52-week low and below its accounting book value, but that low price reflects high risk because the future depends on clinical trials that may or may not succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer